Impact of immune, inflammatory and nutritional indices on outcome in patients with locally advanced cervical cancer treated with definitive (chemo)radiotherapy

This publication has 34 references indexed in Scilit:

• Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
  The Lancet, 2024
• Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
  The Lancet Oncology, 2023
• LBA8 A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial
  Annals of Oncology, 2023
• Systemic immune-inflammation index predicts prognosis and responsiveness to immunotherapy in cancer patients: a systematic review and meta‑analysis
  Clinical and Experimental Medicine, 2023
• Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative
  The Lancet Global Health, 2022
• The utility of pretreatment systemic inflammatory response biomarkers on overall survival of cervical cancer patients stratified by clinical staging
  European Journal of Obstetrics & Gynecology and Reproductive Biology, 2021
• Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies
  Gynecologic Oncology, 2021
• Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients
  Clinical and Translational Oncology, 2018
• The role of the systemic inflammatory response in predicting outcomes in patients with advanced inoperable cancer: Systematic review and meta -analysis
  Critical Reviews in Oncology/Hematology, 2017
• Immunity, Inflammation, and Cancer
  Cell, 2010